Previous Close | 0.3000 |
Open | 0.4000 |
Bid | 0.2500 |
Ask | 0.4500 |
Strike | 2.50 |
Expire Date | 2024-05-17 |
Day's Range | 0.4000 - 0.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 489 |
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates